Drug intelligence / Profile preview

varokibart

Development stage: Discontinued
Lead developer: Teva Pharmaceutical Industries
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

Varokibart (TEV-53275) is a monoclonal antibody developed by Teva Pharmaceutical Industries for the treatment of asthma, specifically targeting eosinophilic and persistent forms of the disease. It acts as an interleukin-5 (IL-5) inhibitor, aiming to reduce inflammation associated with asthma by inhibiting IL-5 activity. The drug was administered subcutaneously in clinical trials and reached phase 2 development before its discontinuation. No orphan drug status or regulatory approvals have been granted[1][5][7].

Other names: varokibart

Targets

IL-5 (Interleukin 5)

Beyond the preview

Go deeper on varokibart.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on varokibart.

Explore the full profile